The immunosuppressive tumor microenvironment in glioblastoma - Top-Institutions - MDSpire

The immunosuppressive tumor microenvironment in glioblastoma

  • By

  • Jing Yang

  • Jie Li

  • Ming Jin

  • Yongping Lu

  • Li Zhang

  • July 2, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Neurosurgery

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #3

    Mass General Brigham Cancer Institute
    Mass General Brigham Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

Original Source(s)

The immunosuppressive tumor microenvironment in glioblastoma

  • by Jing Yang, Jie Li, Ming Jin, Yongping Lu, Li Zhang

  • July 2, 2026

Related Content

Incidental thyroid carcinoma in surgically treated multinodular goiter: a retrospective study

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

  • 1 min
ASCO26: Alicia Morgans, MD, MPH, ARACOG

Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.

  • July 1, 2026

  • 1 min